Use of liposomal anthracyclines in Kaposi's sarcoma
- PMID: 15717737
- DOI: 10.1053/j.seminoncol.2004.08.003
Use of liposomal anthracyclines in Kaposi's sarcoma
Abstract
Conventional chemotherapy regimens for the treatment of advanced Kaposi's sarcoma (KS) show limited efficacy and considerable toxicity. Liposomal anthracyclines with potential utility in KS include pegylated liposomal doxorubicin (Doxil/Caelyx [PLD]), daunorubicin citrate liposome (DaunoXome [DNX]), and nonpegylated liposomal doxorubicin (Myocet [NPLD]). Preclinical data showed that pegylated liposomes accumulate preferentially in highly vascularized KS lesions. In randomized clinical trials, PLD induced higher response rates than did the conventional combination chemotherapy regimens, bleomycin + vincristine (BV) and BV + conventional doxorubicin (ABV); DNX produced a response rate comparable to that of ABV. NPLD has not been compared with conventional chemotherapy for KS. PLD and DNX were associated with less toxicity compared with BV or ABV, including less alopecia and fewer gastrointestinal and neurologic side effects. Grade 3/4 myelosuppression was common with both PLD and DNX; stomatitis and infusion reactions occurred with PLD treatment, but hand-foot syndrome was relatively infrequent in the dose schedules used for KS. Health-related quality of life was improved in several domains in patients treated with PLD or DNX compared with ABV.
Similar articles
-
Randomized phase III trial of liposomal daunorubicin versus doxorubicin, bleomycin, and vincristine in AIDS-related Kaposi's sarcoma.J Clin Oncol. 1996 Aug;14(8):2353-64. doi: 10.1200/JCO.1996.14.8.2353. J Clin Oncol. 1996. PMID: 8708728 Clinical Trial.
-
Treatment of severe or progressive Kaposi's sarcoma in HIV-infected adults.Cochrane Database Syst Rev. 2014;(9):CD003256. doi: 10.1002/14651858.CD003256.pub2. Cochrane Database Syst Rev. 2014. PMID: 25313415 Review.
-
Treatment of severe or progressive Kaposi's sarcoma in HIV-infected adults.Cochrane Database Syst Rev. 2014 Aug 13;8(8):CD003256. doi: 10.1002/14651858.CD003256.pub2. Cochrane Database Syst Rev. 2014. PMID: 25221796 Free PMC article. Review.
-
Cardiac safety of liposomal anthracyclines.Semin Oncol. 2004 Dec;31(6 Suppl 13):161-81. doi: 10.1053/j.seminoncol.2004.08.006. Semin Oncol. 2004. PMID: 15717742 Review.
-
Therapy of special HIV-associated diseases: HCV-HIV-co-infection and AIDS-related Kaposi's sarcoma - official satellite to the 7th European Conference on Clinical Aspects and Treatment of HIV-infection, October 23, 1999 in Lisbon, Portugal.Eur J Med Res. 1999 Dec 16;4(12):507-13. Eur J Med Res. 1999. PMID: 10611054 Clinical Trial.
Cited by
-
Preparation, characterization, pharmacokinetics and anticancer effects of PEGylated β-elemene liposomes.Cancer Biol Med. 2020 Feb 15;17(1):60-75. doi: 10.20892/j.issn.2095-3941.2019.0156. Cancer Biol Med. 2020. PMID: 32296587 Free PMC article.
-
Magnetic Nanoparticles in Cancer Theranostics.Theranostics. 2015 Sep 1;5(11):1249-63. doi: 10.7150/thno.11544. eCollection 2015. Theranostics. 2015. PMID: 26379790 Free PMC article. Review.
-
Fifty-one Kaposi sarcoma patients.Clin Transl Oncol. 2010 Sep;12(9):629-33. doi: 10.1007/s12094-010-0568-7. Clin Transl Oncol. 2010. PMID: 20851804
-
New challenges in the use of nanomedicine in cancer therapy.Bioengineered. 2022 Jan;13(1):759-773. doi: 10.1080/21655979.2021.2012907. Bioengineered. 2022. PMID: 34856849 Free PMC article.
-
Lipid-Based Drug Delivery Systems in Cancer Therapy: What Is Available and What Is Yet to Come.Pharmacol Rev. 2016 Jul;68(3):701-87. doi: 10.1124/pr.115.012070. Pharmacol Rev. 2016. PMID: 27363439 Free PMC article. Review.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical
